Niyanta Kumar

Company: Mersana Therapeutics

Job title: Associate Director

Seminars:

PBPK Modeling & Simulation Predicts Low Drug-Drug Interaction Liability & No Significant Impact of Hepatic Impairment for An ADC With the Payload AF-HPA 2:30 pm

Case study describing a PBPK modeling and simulation approach to predict the impact of drug-drug interactions (DDI) and hepatic impairment on clinical PK of an ADC with an auristatin-based payload (auristatin F-hydroxypropylamide [AF-HPA]) Model development and verification using a combination of in vitro, pre-clinical, and clinical ADME/PK data using mixed ‘bottom-up’ and ‘top-down’ approaches Overview…Read more

day: Conference Day 2